Alexis P Poole1,2,3, Mark E Finnis1,2,3,4, James Anstey4,5, Rinaldo Bellomo3,4,6, Shailesh Bihari7, Vishwanath Biradar8, Sarah Doherty5, Glenn Eastwood3,4,6, Simon Finfer9, Craig J French4,10, Simon Heller11, Michael Horowitz12,13, Palash Kar1,2, Peter S Kruger14,15, Matthew J Maiden1,2,16, Johan Mårtensson17, Colin J McArthur18, Shay P McGuinness19, Paul J Secombe3,20, Antony E Tobin4,21, Andrew A Udy3,22, Paul J Young3,4,23,24, Adam M Deane4,5. 1. Discipline of Acute Care Medicine and. 2. Intensive Care Unit and. 3. Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Prahran, Victoria, Australia. 4. Department of Critical Care, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia. 5. Department of Intensive Care, Royal Melbourne Hospital, Parkville, Victoria, Australia. 6. Department of Intensive Care, Austin Hospital, Heidelberg, Victoria, Australia. 7. Department of Intensive and Critical Care Unit, Flinders Medical Centre, Bedford Park, South Australia, Australia. 8. Department of Intensive Care, Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia. 9. The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. 10. Department of Intensive Care, Western Health, Footscray, Victoria, Australia. 11. Clinical Diabetes, Endocrinology, and Metabolism, University of Sheffield, Sheffield, United Kingdom. 12. Centre for Research Excellence in Translating Nutrition Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia. 13. Medicine and Endocrine Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia. 14. Department of Intensive Care, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. 15. School of Medicine, University of Queensland, Herston, Queensland, Australia. 16. Intensive Care Unit, Barwon Health, Geelong, Victoria, Australia. 17. Section of Anaesthesia and Intensive Care, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. 18. Department of Critical Care Medicine and. 19. Cardiothoracic and Vascular Intensive Care and High Dependency Unit, Auckland District Health Board, Auckland, New Zealand. 20. Department of Intensive Care, Alice Springs Hospital, Alice Springs, Northern Territory, Australia. 21. Department of Intensive Care, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. 22. Department of Intensive Care, The Alfred Hospital, Prahran, Victoria, Australia. 23. Medical Research Institute of New Zealand, Wellington, New Zealand; and. 24. Intensive Care Unit, Wellington Regional Hospital, Wellington, New Zealand.
Abstract
Rationale: Blood glucose concentrations affect outcomes in critically ill patients, but the optimal target blood glucose range in those with type 2 diabetes is unknown. Objectives: To evaluate the effects of a "liberal" approach to targeted blood glucose range during ICU admission. Methods: This mutlicenter, parallel-group, open-label randomized clinical trial included 419 adult patients with type 2 diabetes expected to be in the ICU on at least three consecutive days. In the intervention group intravenous insulin was commenced at a blood glucose >252 mg/dl and titrated to a target range of 180-252 mg/dl. In the comparator group insulin was commenced at a blood glucose >180 mg/dl and titrated to a target range of 108-180 mg/dl. The primary outcome was incident hypoglycemia (<72 mg/dl). Secondary outcomes included glucose metrics and clinical outcomes. Measurements and Main Results: By Day 28, at least one episode of hypoglycemia occurred in 10 of 210 (5%) patients assigned the intervention and 38 of 209 (18%) patients assigned the comparator (incident rate ratio, 0.21 [95% confidence interval (CI), 0.09 to 0.49]; P < 0.001). Those assigned the intervention had greater blood glucose concentrations (daily mean, minimum, maximum), less glucose variability, and less relative hypoglycemia (P < 0.001 for all comparisons). By Day 90, 62 of 210 (29.5%) in the intervention and 52 of 209 (24.9%) in the comparator group had died (absolute difference, 4.6 percentage points [95% CI, -3.9% to 13.2%]; P = 0.29). Conclusions: A liberal approach to blood glucose targets reduced incident hypoglycemia but did not improve patient-centered outcomes. Clinical trial registered with Australian New Zealand Clinical Trials Registry (ACTRN 12616001135404).
Rationale: Blood glucose concentrations affect outcomes in critically ill patients, but the optimal target blood glucose range in those with type 2 diabetes is unknown. Objectives: To evaluate the effects of a "liberal" approach to targeted blood glucose range during ICU admission. Methods: This mutlicenter, parallel-group, open-label randomized clinical trial included 419 adult patients with type 2 diabetes expected to be in the ICU on at least three consecutive days. In the intervention group intravenous insulin was commenced at a blood glucose >252 mg/dl and titrated to a target range of 180-252 mg/dl. In the comparator group insulin was commenced at a blood glucose >180 mg/dl and titrated to a target range of 108-180 mg/dl. The primary outcome was incident hypoglycemia (<72 mg/dl). Secondary outcomes included glucose metrics and clinical outcomes. Measurements and Main Results: By Day 28, at least one episode of hypoglycemia occurred in 10 of 210 (5%) patients assigned the intervention and 38 of 209 (18%) patients assigned the comparator (incident rate ratio, 0.21 [95% confidence interval (CI), 0.09 to 0.49]; P < 0.001). Those assigned the intervention had greater blood glucose concentrations (daily mean, minimum, maximum), less glucose variability, and less relative hypoglycemia (P < 0.001 for all comparisons). By Day 90, 62 of 210 (29.5%) in the intervention and 52 of 209 (24.9%) in the comparator group had died (absolute difference, 4.6 percentage points [95% CI, -3.9% to 13.2%]; P = 0.29). Conclusions: A liberal approach to blood glucose targets reduced incident hypoglycemia but did not improve patient-centered outcomes. Clinical trial registered with Australian New Zealand Clinical Trials Registry (ACTRN 12616001135404).
Entities:
Keywords:
blood glucose; critical illness; diabetes; hypoglycemia; intensive care